Technology | Patient Monitors | August 14, 2015

Nonin Medical Launches Apple iOS-compatible Wireless Finger Pulse Oximeter

Bluetooth Smart connectivity allows remote monitoring of SpO2  readings to help manage COPD

Nonin Medical, NoninConnect Model 3230, Bluetooth Smart, wireless finger pulse oximeter, iOS-compatible, Apple

Image courtesy of Nonin Medical

August 14, 2015 — Nonin Medical Inc. announced it has launched the NoninConnect Model 3230 Bluetooth Smart wireless finger pulse oximeter and Apple iOS mobile app to clinicians and patients outside of the United States.

The NoninConnect wireless finger pulse oximeter combines Nonin's PureSAT pulse oximetry signal processing technology with state-of-the-art Bluetooth Smart (low energy) wireless technology in an easy-to-use connected finger pulse oximeter that measures arterial blood oxygen saturation and pulse rate. The device helps clinicians and patients proactively identify issues for early intervention, helping to avoid re-hospitalization.

With NoninConnect, clinicians can remotely (up to 10 meters) view their patients' SpO2 readings in real time. Patients can easily monitor and share their SpO2 data by downloading the NoninConnect iOS mobile app on their compatible Apple device. Compatible devices include: iPhone 4S and newer, iPad 3 and newer, all iPad Air and iPad Minis, and the iPod Touch 5th edition and newer (with Apple iOS 8.1 or newer installed).

NoninConnect Model 3230 advantages include:

  • An easy-to-read, large, clear user-facing display;
  • A long battery life – allows for up to 2,200 spot checks on two AAA batteries;
  • Simplified wireless pairing to Bluetooth Smart Ready Apple iOS devices;
  • Nonin CorrectCheck Finger Placement Technology, which provides feedback via a digital display if user's finger is not placed correctly in the device; and
  • Nonin SmartPoint Capture and Send Technology, which automatically determines when a high-quality measurement is ready to be wirelessly transmitted.

For more information: www.nonin.com

Related Content

Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
High Intensity Exercise in Teenagers Could Ward Off Heart Disease

Ultrasound image of the carotid artery. Lines in yellow were used to determine arterial diameter and stretching before and following exercise.

News | Cardiac Diagnostics | July 16, 2018
New research published in Experimental Physiology has indicated potential differences in heart health benefits of...
News | Cardiac Diagnostics | June 14, 2018
A team of researchers says it has linked sensitivity to an allergen in red meat to the buildup of plaque in the...
The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

 

Feature | Cardiac Diagnostics | May 07, 2018 | Steven D. Freedman, M.D., Ph.D.
 
Overlay Init